Tags

Type your tag names separated by a space and hit enter

Hyaluronic acid, transforming growth factor-beta1 and hepatic fibrosis in patients with chronic hepatitis C virus and human immunodeficiency virus co-infection.
J Viral Hepat. 2009 Jul; 16(7):513-8.JV

Abstract

Chronic hepatitis C virus (HCV) infection follows an accelerated course in patients co-infected with human immunodeficiency virus (HIV); establishing the extent of liver fibrosis is crucial for disease staging and determining treatment strategy in these patients. The utility of noninvasive markers of fibrosis as alternatives to liver biopsy has not been well-studied in these patients. We evaluated the predictive value of serum transforming growth factor-beta1 (TGF-beta1) and hyaluronic acid (HA) levels for determining the extent of liver fibrosis. Liver biopsies and blood samples were collected from 69 consecutive patients (74% male; median age, 41 years) between May 2005 and November 2006. Serum TGF-beta1 and HA were analysed using commercial kits. Aspartate aminotransferase, alanine aminotransferase and gamma-glutamyl transpeptidase levels were elevated in 81%, 70% and 60% of patients, respectively. Fifty-three patients (90%) were on highly active antiretroviral therapy and the median CD4-positive cell count was 422 cells/microL. The extent of fibrosis according to Scheuer's scoring was 32% F0 (no fibrosis), 16.5% F1, 16.5% F2, 26% F3 and 7% F4 (cirrhosis). Mean serum TGF-beta1 was 36.1 +/- 14.4 ng/mL; mean serum HA was 75.2 +/- 85.0 microg/L. Serum HA was positively associated and significantly correlated with the stage of fibrosis (r = 0.56; P < 0.05). The area under the curve for discriminating mild (F0-F2) from significant (F3-F4) fibrosis in receiver operating analysis using HA was 0.83 (sensitivity, 87%; specificity, 70%). These data suggest that HA is clinically useful for predicting liver fibrosis and cirrhosis in patients co-infected with HCV/HIV. However, serum TGF-beta1 was not predictive of histological damage in co-infected individuals treated with HAART.

Authors+Show Affiliations

Department of Internal Medicine, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma, Barcelona, Spain.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Evaluation Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19200132

Citation

Sanvisens, A, et al. "Hyaluronic Acid, Transforming Growth Factor-beta1 and Hepatic Fibrosis in Patients With Chronic Hepatitis C Virus and Human Immunodeficiency Virus Co-infection." Journal of Viral Hepatitis, vol. 16, no. 7, 2009, pp. 513-8.
Sanvisens A, Serra I, Tural C, et al. Hyaluronic acid, transforming growth factor-beta1 and hepatic fibrosis in patients with chronic hepatitis C virus and human immunodeficiency virus co-infection. J Viral Hepat. 2009;16(7):513-8.
Sanvisens, A., Serra, I., Tural, C., Tor, J., Ojanguren, I., Barluenga, E., Rey-Joly, C., Clotet, B., & Muga, R. (2009). Hyaluronic acid, transforming growth factor-beta1 and hepatic fibrosis in patients with chronic hepatitis C virus and human immunodeficiency virus co-infection. Journal of Viral Hepatitis, 16(7), 513-8. https://doi.org/10.1111/j.1365-2893.2009.01103.x
Sanvisens A, et al. Hyaluronic Acid, Transforming Growth Factor-beta1 and Hepatic Fibrosis in Patients With Chronic Hepatitis C Virus and Human Immunodeficiency Virus Co-infection. J Viral Hepat. 2009;16(7):513-8. PubMed PMID: 19200132.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Hyaluronic acid, transforming growth factor-beta1 and hepatic fibrosis in patients with chronic hepatitis C virus and human immunodeficiency virus co-infection. AU - Sanvisens,A, AU - Serra,I, AU - Tural,C, AU - Tor,J, AU - Ojanguren,I, AU - Barluenga,E, AU - Rey-Joly,C, AU - Clotet,B, AU - Muga,R, Y1 - 2009/02/05/ PY - 2009/2/10/entrez PY - 2009/2/10/pubmed PY - 2009/8/4/medline SP - 513 EP - 8 JF - Journal of viral hepatitis JO - J Viral Hepat VL - 16 IS - 7 N2 - Chronic hepatitis C virus (HCV) infection follows an accelerated course in patients co-infected with human immunodeficiency virus (HIV); establishing the extent of liver fibrosis is crucial for disease staging and determining treatment strategy in these patients. The utility of noninvasive markers of fibrosis as alternatives to liver biopsy has not been well-studied in these patients. We evaluated the predictive value of serum transforming growth factor-beta1 (TGF-beta1) and hyaluronic acid (HA) levels for determining the extent of liver fibrosis. Liver biopsies and blood samples were collected from 69 consecutive patients (74% male; median age, 41 years) between May 2005 and November 2006. Serum TGF-beta1 and HA were analysed using commercial kits. Aspartate aminotransferase, alanine aminotransferase and gamma-glutamyl transpeptidase levels were elevated in 81%, 70% and 60% of patients, respectively. Fifty-three patients (90%) were on highly active antiretroviral therapy and the median CD4-positive cell count was 422 cells/microL. The extent of fibrosis according to Scheuer's scoring was 32% F0 (no fibrosis), 16.5% F1, 16.5% F2, 26% F3 and 7% F4 (cirrhosis). Mean serum TGF-beta1 was 36.1 +/- 14.4 ng/mL; mean serum HA was 75.2 +/- 85.0 microg/L. Serum HA was positively associated and significantly correlated with the stage of fibrosis (r = 0.56; P < 0.05). The area under the curve for discriminating mild (F0-F2) from significant (F3-F4) fibrosis in receiver operating analysis using HA was 0.83 (sensitivity, 87%; specificity, 70%). These data suggest that HA is clinically useful for predicting liver fibrosis and cirrhosis in patients co-infected with HCV/HIV. However, serum TGF-beta1 was not predictive of histological damage in co-infected individuals treated with HAART. SN - 1365-2893 UR - https://www.unboundmedicine.com/medline/citation/19200132/Hyaluronic_acid_transforming_growth_factor_beta1_and_hepatic_fibrosis_in_patients_with_chronic_hepatitis_C_virus_and_human_immunodeficiency_virus_co_infection_ L2 - https://doi.org/10.1111/j.1365-2893.2009.01103.x DB - PRIME DP - Unbound Medicine ER -